The aim for this study was to develop consensus terminology, diagnostic criteria of multimodal imaging and develop a guideline for management of polypoidal choroidal vasculopathy (PCV). A systematic consensus process was conducted to develop updated clinical recommendations for the management of PCV. In order to develop the guidelines, a panel of ten PCV experts nationwide reviewed current evidence, focusing on key randomized controlled trials (EVEREST-II and PLANET), and conducted a systematic literature search to inform the guidelines. Several draft recommendations were evaluated and improved to determine the strength and quality of evidence. Consensus was defined as ≥90% agreement achieved, with multiple voting rounds if needed. The finalized guidelines incorporate the most recent evidence available up to November 30, 2023. The panelists reached an agreement on several aspects of PCV management, including the need for diagnostic criteria, classification, various treatment options and the development of a treatment algorithm. Recommendations are made for the clinical management of PCV based on a professional assessment of current evidence.

Keywords: polypoidal choroidal vasculopathy, anti-vascular endothelial growth factor, photodynamic therapy, surgery

1. Wong, C. W., Wong, T. Y., & Cheung, C. M. (2015). Polypoidal choroidal vasculopathy in Asians. Journal of Clinical Medicine, 4(5), 782–821.
2. Cheung, C. M. G., Lai, T. Y. Y., Teo, K., et al. (2021). Polypoidal choroidal vasculopathy: Consensus nomenclature and non–indocyanine green angiography diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology, 128(3), 443–452.
3. Anantharaman, G., Sheth, J., Bhende, M., et al. (2018). Polypoidal choroidal vasculopathy: Pearls in diagnosis and management. Indian Journal of Ophthalmology, 66(7), 896–908.
4. Chaikitmongkol, V., Sagong, M., Lai, T. Y. Y., et al. (2021). Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: Consensus and recommendations from the Asia-Pacific Vitreo-Retina Society. Asia-Pacific Journal of Ophthalmology, 10(6), 507–518.
5. Dat, D., Hien, N., Quan, N., et al. (2022). Current trends in clinical characteristics, diagnosis, and treatment of polypoidal choroidal vasculopathy: A perspective from Vietnam. Journal of Clinical Medicine, 11(16), Article 4678.
6. Khetan, V., & Palkar, A. (2019). Polypoidal choroidal vasculopathy: An update on current management and review of literature. Taiwan Journal of Ophthalmology, 9(2), 72–92.
7. Koh, A. H. C., Chen, L. J., Chen, S. J., et al. (2013). Polypoidal choroidal vasculopathy: Evidence-based guidelines for clinical diagnosis and treatment. Retina, 33(4), 686–716.
8. Chen, L. J., Cheng, C. K., Yeung, L., et al. (2020). Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan. Journal of the Formosan Medical Association, 119(2), 569–576.
9. Cheung, C. M. G. (2024). Macular neovascularization and polypoidal choroidal vasculopathy: Phenotypic variations, pathogenic mechanisms and implications in management. Eye, 38(4), 659–667.
10. Cheung, C. M. G., Lai, T. Y. Y., Ruamviboonsuk, P., et al. (2018). Polypoidal choroidal vasculopathy. Ophthalmology, 125(5), 708–724.
11. Koh, A., Lee, W. K., Chen, L. J., et al. (2012). EVEREST study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina, 32(8), 1453–1464.
12. Lee, W. K., Iida, T., Ogura, Y., et al. (2018). Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: A randomized clinical trial. JAMA Ophthalmology, 136(7), 786–793.
13. Sheth, J. U., Narayanan, R., Anantharaman, G., et al. (2022). Updated guidelines for the management of polypoidal choroidal vasculopathy: Recommendations from the Indian Polypoidal Choroidal Vasculopathy Panel and the Vitreoretinal Society of India. Indian Journal of Ophthalmology, 70(8), 3102–3111.
14. Koh, A. (2018). Polypoidal choroidal vasculopathy. In Encyclopedia of ophthalmology (pp. 1398–1406). Springer.
15. Wong, T. Y., Ogura, Y., Lee, W. K., et al. (2019). Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: Two-year results of the aflibercept in polypoidal choroidal vasculopathy study. American Journal of Ophthalmology, 204, 80–89.
16. Maruko, I., Ogasawara, M., Yamamoto, A., et al. (2020). Two-year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration. Ophthalmology Retina, 4(8), 767–776.
17. Okada, A. A., Takahashi, K., Ohji, M., et al. (2022). Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in the ALTAIR study: 96-week outcomes in the polypoidal choroidal vasculopathy subgroup. Advances in Therapy, 39(6), 2984–2998.
18. Wang, W. R., Elkins, K., Oh, A., et al. (2014). Structural basis for resistance to diverse classes of NAMPT inhibitors. PLoS One, 9(10), Article e109366.
19. Koh, A., Lai, T. Y. Y., Takahashi, K., et al. (2017). Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: A randomized clinical trial. JAMA Ophthalmology, 135(11), 1206–1213.
20. Lim, T. H., Lai, T. Y. Y., Takahashi, K., et al. (2020). Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial. JAMA Ophthalmology, 138(9), 935–942.
21. Lee, M. W., Yeo, I., Wong, D., et al. (2009). Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. Eye, 23(1), 145–148.
22. Oishi, A., Kojima, H., Mandai, M., et al. (2013). Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. American Journal of Ophthalmology, 156(4), 644–651.e1.
23. Chakraborty, D., Maiti, A., Sengupta, S., et al. (2022). Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes—A multicenter retrospective study. Indian Journal of Ophthalmology, 70(4), 1295–1299.
24. Dugel, P. U., Koh, A., Ogura, Y., et al. (2020). HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology, 127(1), 72–84.
25. Dugel, P. U., Singh, R. P., Koh, A., et al. (2021). HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology, 128(1), 89–99.
26. Garweg, J. G., Keiper, J., Pfister, I. B., et al. (2023). Functional outcomes of brolucizumab-induced intraocular inflammation involving the posterior segment—A meta-analysis and systematic review. Journal of Clinical Medicine, 12(14), Article 4671.
27. Monés, J., Srivastava, S. K., Jaffe, G. J., et al. (2021). Risk of inflammation, retinal vasculitis, and retinal occlusion–related events with brolucizumab. Ophthalmology, 128(7), 1050–1059.
28. Cho, J. H., Ryoo, N. K., Cho, K. H., et al. (2016). Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy. American Journal of Ophthalmology, 169, 79–88.
29. Cho, H. J., Kim, K., Lim, S. H., et al. (2020). Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 104(10), 1443–1447.
30. Yuzawa, M., Mori, R., & Haruyama, M. (2003). A study of laser photocoagulation for polypoidal choroidal vasculopathy. Japanese Journal of Ophthalmology, 47(4), 379–384.
31. Gemmy Cheung, C. M., Yeo, I., Li, X., et al. (2013). Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. American Journal of Ophthalmology, 155(2), 295–304.e1.
32. Sen, P., Kumar, S. V., Bhende, M., et al. (2016). Combined argon laser photocoagulation and antivascular endothelial growth factor for management of macular polypoidal choroidal vasculopathy. Oman Journal of Ophthalmology, 9(3), 139–143.
33. Schmidt, J. C., Meyer, C. H., & Hörle, S. (2004). Massive subretinal hemorrhages. A challenge for vitreous body surgeons. Der Ophthalmologe, 101(6), 584–588.
34. Fine, H. F., Iranmanesh, R., Del Priore, L. V., et al. (2010). Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration. Retina, 30(10), 1588–1594.
35. Yiu, G., & Mahmoud, T. H. (2014). Subretinal hemorrhage. Developments in Ophthalmology, 54, 213–222.
36. Stanescu-Segall, D., Balta, F., & Jackson, T. L. (2016). Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature. Survey of Ophthalmology, 61(1), 18–32.
37. Chang, W., Garg, S. J., Maturi, R., et al. (2014). Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration. American Journal of Ophthalmology, 157(6), 1250–1257.
38. Driscoll, S., & Garg, S. J. (2014). Managing submacular hemorrhage. Review of Ophthalmology. https://www.reviewofophthalmology.com/article/managing-submacular-hemorrhage
39. Saito-Uchida, S., Inoue, M., Koto, T., et al. (2021). Vitrectomy combined with subretinal injection of tissue plasminogen activator for successful treatment of massive subretinal hemorrhage. European Journal of Ophthalmology, 31(5), 2588–2595.
40. Kimura, S., Morizane, Y., Hosokawa, M. M., et al. (2019). Outcomes of vitrectomy combined with subretinal tissue plasminogen activator injection for submacular hemorrhage associated with polypoidal choroidal vasculopathy. Japanese Journal of Ophthalmology, 63(5), 382–388.
41. Kim, J. H., Kim, J. W., Kim, C. G., et al. (2020). Long-term clinical course after vitrectomy for breakthrough vitreous hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Scientific Reports, 10(1), Article 359.
42. Inoue, N., Kato, A., Araki, T., et al. (2022). Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: A retrospective multicenter survey. PLoS One, 17(7), Article e0271447.
43. Lewis, H. (1994). Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. American Journal of Ophthalmology, 118(5), 559–568.
44. Chawla, H., Blair, K., & Vohra, V. (2023). Polypoidal choroidal vasculopathy. In StatPearls. StatPearls Publishing.
45. Bo, Q. Y., Yan, Q., Shen, M. X., et al. (2019). Appearance of polypoidal lesions in patients with polypoidal choroidal vasculopathy using swept-source optical coherence tomographic angiography. JAMA Ophthalmology, 137(6), 642–650.
46. Sen, P., Manayath, G., Shroff, D., et al. (2023). Polypoidal choroidal vasculopathy: An update on diagnosis and treatment. Clinical Ophthalmology, 17, 53–70.
47. Liu, S. Y., & Chhabra, R. (2022). Real-world outcomes of combined therapy of photodynamic therapy with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy. Eye, 36(10), 1934–1939.
48. Zhao, X. Y., Zhang, W. F., Meng, L. H., et al. (2021). The polyp regression rate and treatment prognosis of different interventions for polypoidal choroidal vasculopathy: A systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 259(4), 855–872.
49. Choi, J., Park, J. B., Lee, J., et al. (2026). Three-year outcomes of polypoidal choroidal vasculopathy according to polypoidal regression on optical coherence tomography angiography. Eye, 40(4), 473–479.